The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×5•Originally published 7 May 2026•Updated 8 May 2026•

1 min read

US Biotech and Energy Sectors Show Strong Growth in Q1 2026 Earnings Kickoff

Key Facts

1Iovance Biotherapeutics reported Q1 revenue of approximately $71M, representing 45% year-over-year growth.

2Akebia Therapeutics reported that Vafseo net product revenues grew 60% in Q1 2026 compared to Q4 2025.

26 days ago

Version History

3 additional sources confirmed this story

Version 526 days ago

What changed: Added Q1 2026 financial results and specific sales growth metrics for bioAffinity Technologies (BIAF).

Version 426 days ago

What changed: Updated the story to include the 13% collapse in Iovance Biotherapeutics (IOVA) stock price and its impact on market capitalization.

Version 327 days ago

What changed: Updated the story to include Aligos Therapeutics' Q1 results, featuring its $420M licensing deal and FDA Fast Track designation.

Version 228 days ago

What changed: Updated the story to include Aardvark Therapeutics' voluntary clinical program pause due to cardiac safety observations and its current cash runway details.

Version 128 days ago

What changed: Added Q1 2026 financial results for ImmunityBio (IBRX), including product revenue growth and cash reserve details.

The Q1 2026 earnings season presents a mixed landscape for the US biotech and energy sectors, highlighted by significant sales growth and clinical milestones. bioAffinity Technologies (BIAF) emerged as a top performer, reporting a 146% year-over-year increase in CyPath Lung unit sales as clinical adoption for early-stage lung disease detection expanded. Meanwhile, Aligos Therapeutics maintained positive momentum with an FDA Fast Track Designation, but Iovance Biotherapeutics saw its stock plunge 13% to $3.55 amid financial performance concerns. Akebia Therapeutics reported a 60% surge in Vafseo sales, and U.S. Energy Corp strengthened its position through a strategic helium offtake agreement. These updates underscore a dynamic environment where robust sales metrics from firms like BIAF are being weighed against broader market volatility.